001433171 000__ 03689cam\a2200637\i\4500
001433171 001__ 1433171
001433171 003__ OCoLC
001433171 005__ 20230309003552.0
001433171 006__ m\\\\\o\\d\\\\\\\\
001433171 007__ cr\un\nnnunnun
001433171 008__ 201207t20212021si\a\\\\o\\\\\000\0\eng\d
001433171 019__ $$a1226532208$$a1226582678$$a1228843477$$a1229918959$$a1238201111$$a1244634797$$a1250576628
001433171 020__ $$a9789811584237$$q(electronic book)
001433171 020__ $$a9811584230$$q(electronic book)
001433171 020__ $$z9789811584220$$q(hardcover)
001433171 020__ $$z9811584222$$q(hardcover)
001433171 0247_ $$a10.1007/978-981-15-8423-7$$2doi
001433171 035__ $$aSP(OCoLC)1228650104
001433171 040__ $$aSFB$$beng$$erda$$epn$$cSFB$$dOCLCO$$dEBLCP$$dOCLCF$$dGW5XE$$dYDX$$dUPM$$dBDX$$dOCLCO$$dDCT$$dN$T$$dOCL$$dDKU$$dOCLCO$$dIBI$$dOCLCO$$dOCLCQ$$dCASUM
001433171 049__ $$aISEA
001433171 050_4 $$aRC270.3.T65$$bA665 2021eb
001433171 08204 $$a616.99/407575$$223
001433171 24500 $$aApplications of FDG PET in oncology :$$bbest clinical practice /$$cHirofumi Fujii, Hiroyuki Nakamura, Seiei Yasuda, editors.
001433171 264_1 $$aSingapore :$$bSpringer,$$c[2021]
001433171 264_4 $$c©2021
001433171 300__ $$a1 online resource (vii, 147 pages) :$$billustrations (chiefly color)
001433171 336__ $$atext$$btxt$$2rdacontent
001433171 337__ $$acomputer$$bc$$2rdamedia
001433171 338__ $$aonline resource$$bcr$$2rdacarrier
001433171 347__ $$atext file
001433171 347__ $$bPDF
001433171 5050_ $$a1 Overview.-2 Lung cancer.-3 Breast cancer -- 4 Head and neck cancer.-5 Gastrointestinal cancer including GIST -- 6 Pancreatic cancer -- 7 Urological cancer -- 8 Malignant bone and soft tissue tumors -- 9 Skin cancer including malignant melanoma -- 10 Malignant lymphoma.
001433171 506__ $$aAccess limited to authorized users.
001433171 520__ $$aThis book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management. The book is written by expert clinicians from Japan, where the universal public health insurance system ensures that FDG PET is widely used in routine oncological practice and cancer screening. It represents an unrivaled and comprehensive resource that will be of value for all healthcare professionals in the field of clinical oncology.
001433171 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed February 16, 2021).
001433171 650_0 $$aTomography, Emission.
001433171 650_0 $$aCancer$$xTomography.
001433171 650_0 $$aOncology.
001433171 650_0 $$aRadiology.
001433171 650_0 $$aCancer$$xResearch.
001433171 650_6 $$aTomographie par émission.
001433171 650_6 $$aCancer$$xTomographie.
001433171 650_6 $$aCancérologie.
001433171 650_6 $$aRadiologie.
001433171 650_6 $$aCancer$$xRecherche.
001433171 655_0 $$aElectronic books.
001433171 7001_ $$aFujii, H.$$q(Hirofumi),$$eeditor.
001433171 7001_ $$aNakamura, Hiroyuki,$$eeditor.
001433171 7001_ $$aYasuda, Seiei,$$eeditor.
001433171 77608 $$iPrint version:$$z9811584222$$z9789811584220
001433171 852__ $$bebk
001433171 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-15-8423-7$$zOnline Access$$91397441.1
001433171 909CO $$ooai:library.usi.edu:1433171$$pGLOBAL_SET
001433171 980__ $$aBIB
001433171 980__ $$aEBOOK
001433171 982__ $$aEbook
001433171 983__ $$aOnline
001433171 994__ $$a92$$bISE